Synaptogenix Stock Price, News & Analysis

Synaptogenix, a biopharmaceutical company focused on neurodegenerative disorders, is set to present at the ThinkEquity Conference on October 26, 2022, at the Mandarin Oriental Hotel in New York. Dr. Daniel L. Alkon, President and Chief Scientific Officer, will discuss the company's NIH-supported Phase 2 clinical trial of Bryostatin-1 for treating advanced Alzheimer's disease. Topline data from this trial is expected in the current quarter. The company aims to develop therapies that improve Alzheimer's patients' conditions and prevent disease progression.

Synaptogenix, Inc. (Nasdaq: SNPX) announced that it anticipates results from its Phase 2 clinical trial of Bryostatin-1 for advanced Alzheimer's disease in Q4 2022. The company highlights its commitment to restoring cognitive function, contrasting its approach with Biogen and Eisai's method of slowing disease progression. Bryostatin-1 aims to regenerate synaptic networks, potentially leading to improved cognitive performance. The lead compound has been previously tested in over 1,500 individuals, providing a strong safety database to guide future clinical trials.

Synaptogenix, Inc. (Nasdaq: SNPX) announced that Dr. Daniel L. Alkon, President and CSO, will appear on TD Ameritrade Network's "Trading 360" on August 12, 2022, at 10:30 AM Eastern. Dr. Alkon will discuss the advancement of treatments for Alzheimer's disease and the Phase 2b clinical trial of the lead drug, Bryostatin-1. Synaptogenix holds Orphan Drug Designation for Bryostatin-1 for treating Fragile X syndrome. The Company emphasizes ongoing clinical developments and the potential future applications of Bryostatin-1 in neurodegenerative diseases.

Synaptogenix (Nasdaq: SNPX) announced changes to its Scientific Advisory Board (SAB) ahead of the Phase 2b clinical trial data for Bryostatin-1 in advanced Alzheimer's patients. The SAB includes experts such as Dr. George Perry and Dr. Marwan Sabbagh, who will guide the company's therapeutic developments. CEO Alan Tuchman emphasized the critical expertise of the SAB in preparing for the upcoming data. The company has also received Orphan Drug Designation for Bryostatin-1 targeting Fragile X syndrome, enhancing its research credentials.

Synaptogenix, Inc. (Nasdaq: SNPX) announced a corporate update conference call scheduled for July 26, 2022, at 4:30 PM ET. The call will be led by CEO Dr. Alan Tuchman and President Dr. Daniel Alkon, with a live Q&A session following their remarks. The call will discuss updates on the company's development of regenerative therapeutics for neurodegenerative disorders, particularly focusing on Bryostatin-1 for Multiple Sclerosis and Alzheimer's disease. Forward-looking statements regarding clinical trials are included, highlighting potential risks and uncertainties.

Synaptogenix, Inc. (Nasdaq: SNPX) has initiated dosing in its open-label dose optimization clinical trial for Bryostatin-1, aimed at treating Alzheimer's disease (AD). This trial follows promising results from two pilot Phase 2 studies showing significant cognitive improvements over placebo. The company plans to release topline data from its NIH-sponsored Phase 2b trial in Q4 2022. CEO Alan Tuchman expressed optimism about Bryostatin's potential to address synaptic loss, while emphasizing the need for dose optimization to enhance treatment outcomes.

Synaptogenix, a biopharmaceutical company focused on neurodegenerative disorders, announced that Dr. Daniel Alkon will present at the Cell Symposium in Spain on May 17, 2022. The presentation is titled "Bryostatin Enhances Synaptic Growth through Epigenetic Regulation of ApoE Alleles." This research aims to extend the therapeutic benefits of Bryostatin for Alzheimer's patients. Currently, the company is conducting a NIH-supported Phase 2 trial for advanced Alzheimer's patients who have shown improvement with Bryostatin treatment.

Synaptogenix, Inc. (Nasdaq: SNPX) has completed enrollment of 100 patients in its NIH-sponsored Phase 2b clinical trial of Bryostatin-1, targeting advanced Alzheimer's disease. Topline results are expected in Q4 2022. The Data Safety Monitoring Board reported no adverse safety issues, suggesting a favorable safety profile for the drug. Past trials indicated significant cognitive enhancement for treated patients. With extended dosing in the current trial, the company anticipates promising outcomes that could lead to further clinical development.

Synaptogenix, Inc. (Nasdaq: SNPX) announced the publication of a peer-reviewed article highlighting Bryostatin's potential to enhance blood vessel health, critical for Alzheimer's disease (AD) treatment. The study, led by researchers from Thomas Jefferson University with NIH collaboration, shows Bryostatin increased micro-vessels in AD mouse models, indicating promise for ongoing Phase 2b clinical trials of Bryostatin-1 in AD patients. The findings emphasize Bryostatin's dual benefits in restoring vascular health and oxidative balance, presenting a hopeful prospect for Alzheimer's care.